AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01389713
Drug: GnRH analog and recombinant human FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
Trial: NCT01569113
Drug: placebo + ethinylestradiol/levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
Trial: NCT03420092
Drug: Selected form (Form 2 - 5) of AZD5718 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
Trial: NCT01085981
Drug: arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
Trial: NCT01085981
Drug: Topical study cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
Trial: NCT01134549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single intravenous (IV) injection
Trial: NCT01290965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet given once or three times daily for 15 consecutive days
Trial: NCT03441100
Drug: IMA202 Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
Trial: NCT03067168
Drug: normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
Trial: NCT02994836
Drug: Anti-TNF discontinuation: Physiological saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
Trial: NCT02994836
Drug: Anti-TNF discontinuation: Physiological saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
Trial: NCT03013036
Drug: fentanyl and rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02268604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01080820
Drug: CMX157
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
Trial: NCT01080820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
Trial: NCT01924286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03944954
Drug: Marinol 10Mg Capsule TMS Sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individuals will receive 10mg dose and sham TMS.
Trial: NCT00613457
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
Trial: NCT00613457
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/sqm i.v. x 4 doses in Protocol II and III
Trial: NCT00613457
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
Trial: NCT00613457
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
Trial: NCT00763321
Drug: ABT-712
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-712 extended-release tablet
Trial: NCT00763321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT01302873
Drug: BGG492A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02486757
Drug: transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01554930
Drug: Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
Trial: NCT01017952
Drug: FF/GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
Trial: NCT01017952
Drug: GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long Acting Beta Agonist(LABA) Inhalation Powder
Trial: NCT01965496
Drug: PEX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A injection administered subcutaneously
Trial: NCT02265679
Drug: BIIL 284 BS, low dose, pediatric patients
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02265679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03315533
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
Trial: NCT02022306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02793232
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo suspension administered as single dose
Trial: NCT00235898
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02793232
Drug: Placebo multiple ascending dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo suspension administered daily for 14 consecutive days.
Trial: NCT03310021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01962805
Drug: Proellex Formulation A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01962805
Drug: Proellex Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01767155
Drug: AEZS-108 / zoptarelin doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
Trial: NCT01767155
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
Trial: NCT03928600
Drug: Dinoprostone 10mg insert OR
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Application for 24h of Dinoprostone 10mg insert
Trial: NCT01337427
Drug: BIIB017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
Trial: NCT00177580
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02518750
Drug: Intrathecal Triples
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT as ITMHA.
Trial: NCT02518750
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intrathecally (IT) or IV.
Trial: NCT02518750
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT00264914
Drug: SR121463B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01800838
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo PDT
Trial: NCT01905605
Drug: phosphatidylcholine supplementation
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phosphatidylcholine concentrate 700 mg twice per day
Trial: NCT01905605
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
Trial: NCT00067327
Drug: Inosine
RxNorm normalized name: Inosine
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01753362
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00974350
Drug: SABER-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
Trial: NCT01807026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02788357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
Trial: NCT01627639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00694044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 21 days
Trial: NCT03248128
Drug: FF/VI via ELLIPTA DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
Trial: NCT03248128
Drug: FF via ELLIPTA DPI
RxNorm normalized name: Eclipta prostrata leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
Trial: NCT01608906
Drug: low dose intravenous heparin (LDIVH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
Trial: NCT01608906
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
Trial: NCT04234178
Drug: Epidural
RxNorm normalized name: Epidural 17g 3.5"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
Trial: NCT03892447
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine3～5 ug/kg·min,iv,3 h/d,14d
Trial: NCT03254966
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT03254966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00804973
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules, once
Trial: NCT00301327
Drug: Summers 5% L.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02002130
Drug: Placebo GABA and Placebo GAD-alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
Trial: NCT00169130
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00169130
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01087567
Drug: Routine Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
Trial: NCT02061358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, single dose
Trial: NCT00473616
Drug: AZD7762
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01812239
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
Trial: NCT01458886
Drug: Placebo matching Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs a.m. via Respimat inhaler
Trial: NCT00492583
Drug: Bifidobacterium lactis (BB-12)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
Trial: NCT00492583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
Trial: NCT01939743
Drug: Diclofenac suppository plus lidocaine gel
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04403282
Drug: Eflornithine Topical
RxNorm normalized name: eflornithine topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
Trial: NCT04403282
Drug: Placebo Eflornithine Topical
RxNorm normalized name: eflornithine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will apply placebo to one side of beard and eflornithine to other side for 16 weeks.
Trial: NCT00824512
Drug: EGb 761 120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761® 120 mg bid, orally for 12 to 14 weeks
Trial: NCT00824512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet BID, orally for 12 to 14 weeks
Trial: NCT01336088
Drug: ADX48621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01336088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00095160
Drug: 852A
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03781596
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
Trial: NCT01647620
Drug: DPOC-4088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
Trial: NCT01647620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 10-day oral dosing of matching placebo prolonged release tablet.
Trial: NCT00795314
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
Trial: NCT00751023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 tablets daily for 4 weeks
Trial: NCT02201316
Drug: GR107719B (Formulation 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
Trial: NCT02201316
Drug: GR107719B (Formulation 2)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
Trial: NCT00759707
Drug: L-N^G monomethyl arginine (L-NMMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
Trial: NCT02208973
Drug: PBF-680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5, 10, 20, 40 and 60 mg of PBF-680
Trial: NCT02208973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
Trial: NCT00615615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
Trial: NCT01468688
Drug: STI571
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01468688
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 combination therapy
Trial: NCT00948909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intervention
Trial: NCT00948909
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental intervention
Trial: NCT00842309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
Trial: NCT04691505
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is used as the reference group.
Trial: NCT00088517
Drug: [11C]NNC-112
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05745584
Drug: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
Trial: NCT00427154
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, inhalation.
Trial: NCT00204451
Drug: 50 mg ethinyl estradiol/0.5 mg levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01742208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
Trial: NCT04173923
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
Trial: NCT01929915
Drug: Intravenous patient controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
Trial: NCT01409603
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04586985
Drug: FTX-6058/placebo oral capsule(s)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive FTX-6058 or matching placebo.
Trial: NCT04586985
Drug: FTX-6058 - Two Dosing Periods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive FTX-6058
Trial: NCT00693160
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single intrathecal injection of ketorolac 2 mg
Trial: NCT00693160
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subject will receive a placebo (preservative free normal saline) spinal injection